Literature DB >> 30567266

Catatonia due to alprazolam withdrawal.

Siddharth Iyengar1, Charles Bornmann2, Farid Abdelmalak2, Tulisa LaRocca2.   

Abstract

A 50-year-old man with multiple psychiatric comorbidities including major depressive disorder and general anxiety disorder presented to the emergency room (ER) with altered mental status, immobility and mutism. The patient was unresponsive to commands and unable to provide any history. In the ER he was given a provisional diagnosis of cerebrovascular accident (CVA). Vital signs on admission were stable. On physical examination, he exhibited grimacing, muscle rigidity and areflexia. Workup for CVA and infectious aetiology was unremarkable and the patient's urine toxicology screen was negative. History from the patient's family revealed that 4 days prior to presentation, the patient had discontinued his prescribed dose of alprazolam 1 mg four times per day. The patient was diagnosed with catatonia due to benzodiazepine withdrawal and had gradual return to baseline with administration of lorazepam 1 mg intravenous three times per day. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  contraindications and precautions; drugs: psychiatry; medical management; psychiatry

Mesh:

Substances:

Year:  2018        PMID: 30567266      PMCID: PMC6301493          DOI: 10.1136/bcr-2018-227175

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Catatonia Associated With Alprazolam Discontinuation in a Young Man With Cardiac Cirrhosis.

Authors:  Brian Holoyda; Glen Xiong
Journal:  J Clin Psychopharmacol       Date:  2015-12       Impact factor: 3.153

2.  Clonazepam withdrawal-induced catatonia.

Authors:  Mark Brown; Scott Freeman
Journal:  Psychosomatics       Date:  2009 May-Jun       Impact factor: 2.386

3.  Resurgence of catatonia following tapering or stoppage of lorazepam - A case series and implications.

Authors:  Syed Farooq Ali; Guru S Gowda; T S Jaisoorya; Suresh Bada Math
Journal:  Asian J Psychiatr       Date:  2017-04-04

Review 4.  Catatonia in DSM-5.

Authors:  Rajiv Tandon; Stephan Heckers; Juan Bustillo; Deanna M Barch; Wolfgang Gaebel; Raquel E Gur; Dolores Malaspina; Michael J Owen; Susan Schultz; Ming Tsuang; Jim van Os; William Carpenter
Journal:  Schizophr Res       Date:  2013-06-24       Impact factor: 4.939

Review 5.  Catatonia: clinical aspects and neurobiological correlates.

Authors:  Jessica Daniels
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2009       Impact factor: 2.198

6.  Clinical manifestations, diagnosis, and empirical treatments for catatonia.

Authors:  Mahendra T Bhati; Catherine J Datto; John P O'Reardon
Journal:  Psychiatry (Edgmont)       Date:  2007-03

7.  Catatonia after benzodiazepine withdrawal.

Authors:  P I Rosebush; M F Mazurek
Journal:  J Clin Psychopharmacol       Date:  1996-08       Impact factor: 3.153

8.  Lorazepam withdrawal catatonia: a case report.

Authors:  Thanapal Sivakumar; Anil Yadav; Mamta Sood; Sudhir K Khandelwal
Journal:  Asian J Psychiatr       Date:  2013-06-12

9.  Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review.

Authors:  John Bilbily; Betsy McCollum; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2017-03-15

Review 10.  Review of withdrawal catatonia: what does this reveal about clozapine?

Authors:  Matthew Lander; Tarun Bastiampillai; Jitender Sareen
Journal:  Transl Psychiatry       Date:  2018-07-31       Impact factor: 6.222

View more
  2 in total

1.  Management and outcomes of catatonia: A prospective study in urban South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan van Wyk
Journal:  SAGE Open Med       Date:  2022-06-20

2.  A prospective descriptive study on prevalence of catatonia and correlates in an acute mental health unit in Nelson Mandela Bay, South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan Van Wyk
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.